Multicenter retrospective analysis shows promising efficacy of glofitamab in heavily pretreated MCL, suggesting a new treatment option.
Background Relapsed or refractory mantle cell lymphoma (r/r MCL) remains difficult to treat despite therapeutic advances. Methods This multicenter retrospective study included 10 patients with r/r MCL treated with glofitamab across five sites in Austria and Italy before European approval (January 2023–May 2024). Results Patients were heavily pretreated (median 4.5 prior lines; 5/10 post‐CAR‐T). After a median of five cycles, responses were observed in 7/9 evaluable patients, including complete response in 4/9. Cytokine‐release syndrome occurred in 7/10 (mostly Grade 1–2), including grade 3 events in 2/10, while ICANS occurred in 2/10 patients, including one Grade 4 event. Three patients received glofitamab as bridging therapy and all proceeded to CAR‐T infusion. Conclusion Glofitamab showed encouraging activity and manageable toxicity in heavily pretreated MCL, including as bridging therapy to CAR‐T‐cell treatment. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.
No takes yet. Share an insight, caveat, or question.
Rotter et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: